Dr David Reddy is chief executive officer of Medicines for Malaria Venture (MMV). Under his leadership, this not-for-profit research foundation has brought forward and delivered six new antimalarial drugs to malaria-endemic countries and broadened its malaria drug pipeline to include nine novel compounds in clinical development. MMV is guided by a board and donor-approved five-year strategy to develop and deliver new antimalarials to meet the needs of vulnerable populations. Over the last five years Dr Reddy and the MMV team have raised over $350 million to support this strategy, whose ultimate goal is to support the elimination and eventual eradication of the disease.
A dual New Zealand/Swiss national, Dr Reddy has 20 years of experience in the development and commercialization of medicines for the treatment of infectious diseases. His resume includes successful leadership of drug development teams, licensing and alliance management, market analytics and business planning, product and disease area management, and interfacing with governments, NGOs, and patient advocacy groups around access to medicines for priority diseases including HIV/AIDS and pandemic influenza. Dr Reddy earned a Doctor of Philosophy in Cellular and Molecular Biology from the University of Auckland, New Zealand.